- Home
- ABT vs GILD Comparison
ABT vs GILD Comparison
Compare ABT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABT | GILD |
|---|---|---|
| Founded | 1888 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6B | 187.5B |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ABT | GILD |
|---|---|---|
| Price | $109.99 | $143.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | $141.00 | ★ $143.50 |
| AVG Volume (30 Days) | ★ 7.4M | 6.4M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.27% | 2.26% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 3.72 | ★ 6.78 |
| Revenue | ★ $44,328,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $8.92 | $4.68 |
| Revenue Next Year | $7.39 | $6.10 |
| P/E Ratio | $29.80 | ★ $21.40 |
| Revenue Growth | 5.67 | ★ 9.98 |
| 52 Week Low | $105.27 | $95.30 |
| 52 Week High | $139.15 | $157.29 |
Technical Indicators
Market Signals| Indicator | ABT | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 47.23 |
| Support Level | $105.27 | $143.09 |
| Resistance Level | $113.76 | $157.29 |
| Average True Range (ATR) | 1.85 | 3.28 |
| MACD | -0.03 | -1.54 |
| Stochastic Oscillator | 17.82 | 8.16 |
Price Performance
Historical ComparisonAbout ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).